CINCINNATI--(BUSINESS WIRE)--Camargo Pharmaceutical Services successfully completed five Food and Drug Administration (FDA) pre-IND meetings for 505(b)(2) products in the month of June, including successful meetings with two of India’s top 10 largest pharmaceutical companies.
